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AbstrAct
AIRE is involved in susceptibility to melanoma perhaps regulating T cell immunity 
against melanoma antigens (MA). To address this issue, AIRE and MAGEB2 expressions 
were measured by real time PCR in medullary thymic epithelial cells (mTECs) from two 
strains of C57BL/6 mice bearing either T or C allelic variant of the rs1800522 AIRE 
SNP. Moreover, the extent of apoptosis induced by mTECs in MAGEB2-specific T cells 
and the susceptibility to in vivo melanoma B16F10 cell challenge were compared in 
the two mouse strains. 
The C allelic variant, protective in humans against melanoma, induced lower AIRE 
and MAGEB2 expression in C57BL/6 mouse mTECs than the T allele. Moreover, mTECs 
expressing the C allelic variant induced lower extent of apoptosis in MAGEB2-specific 
syngeneic T cells than mTECs bearing the T allelic variant (p < 0.05). Vaccination 
against MAGEB2 induced higher frequency of MAGEB2-specific CTL and exerted 
higher protective effect against melanoma development in mice bearing the CC AIRE 
genotype than in those bearing the TT one (p < 0.05). These findings show that allelic 
variants of one AIRE SNP may differentially shape the MA-specific T cell repertoire 
potentially influencing susceptibility to melanoma.
INtrODUctION
AIRE gene, located in the 21q22.3 region, encodes 
a powerful transcriptional transactivator [1-4]. It is highly 
expressed in thymus [5] by a subpopulation of medullary 
thymic epithelial cells (mTECs) [6]. In mTECs AIRE 
is responsible for the expression of genes known as 
promiscuously expressed genes encoding tissue-restricted 
self-antigens (TRAs) [7, 8]. The expression of TRAs 
in mTECs allows negative selection of auto-reactive 
lymphocytes having high affinity for the cognate auto-
antigen, but not of those with low/intermediate affinity [9]. 
Hence, potentially auto-reactive T cell clones specific for 
several auto-antigens, including melanoma antigens (MA) 
such as MAGE [6, 10, 11], are exported to the periphery. 
AIRE gene is polymorphic and its polymorphisms 
may be associated to disease susceptibility [12-14]. 
Recently we observed that reciprocal variant alleles 
of AIRE single nucleotide polymorphisms (SNPs) 
rs1055311, rs1800520 and rs1800522 are differently 
present in healthy subjects and in melanoma patients [15]. 
Interestingly, the protective allelic variants of these SNPs 
are associated with increased frequency of two MAGE-1-
specific T-cell clonotypes in healthy subjects, suggesting 
that their protective effect may be mediated by selection/
expansion of MA-specific T cells. In the present study we 
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have investigated this mechanism, taking advantage of two 
strains of C57BL/6 mice each of which bears selectively 
one of the two variant alleles of rs1800522 AIRE SNP. 
MAGEB2 gene, expressed both by C57BL/6 mice [16] and 
B16F10 melanoma cells (our observation), was selected 
as a reference antigen for measuring MA-specific T cell 
response because MAGE antigens are AIRE-dependent 
antigens expressed by mTECs [17-21] and have been 
suggested to be tumor rejection antigens [22, 23]. The 
results show that the two variant alleles of the rs1800522 
AIRE SNP differently modulate MAGEB2-specific T 
cell survival and in vivo susceptibility to melanoma. 
This finding suggests a role for AIRE polymorphisms in 
melanoma protection or susceptibility through differential 
shaping of MA-specific T cell repertoire.
 rEsULts
Identification of a homologous SNP in human and 
mouse AIRE gene
In our recent analysis of AIRE SNPs in patients 
with melanoma we have found that three SNPs are 
associated with low risk of melanoma development [15]. 
To test whether these polymorphisms were present in 
mouse AIRE gene, we aligned mouse and human AIRE 
sequences using the UCSC database (www.genome.ucsc.
edu/cgi-bin/hgBlat). We found that mouse AIRE gene 
sequence between 13207 and 13241 base pairs of exon 
14 (located in chromosome 10), has a 86% homology 
with that between 11650 and 11690 base pairs of the 
corresponding exon of human AIRE gene (located in 
chromosome 21) (Figure 1A) where rs1800522 SNP is 
mapped. The possible genotypes of rs1800522 SNP are 
CC, TT and CT. To test whether this polymorphism was 
Figure 1: Analysis of AIRE genomic sequences encompassing the rs1800522 SNP in humans and mice. A. Comparison 
of human and mouse AIRE gene sequences. Side by side sequence alignment of the region comprised between nucleotides 13207 and 
13241 downstream of the translation initiation codon of human AIRE gene on chromosome 21, containing the rs1800522 SNP, and of that 
comprised between nucleotides 11650 and 11690 of mouse AIRE gene on chromosome 10 shows the identity of the two regions. Data were 
obtained from UCSC database. B. Sequence analysis of the exon 14 of AIRE gene in C57BL/6 mice strain 1 (upper row) and strain 2 (lower 
row). The analysis was performed on DNA extracted from mTECs of each of the two strains of C57BL/6 mice. 
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present in the mouse gene, we sequenced exon 14 of 
mouse AIRE gene in C57BL/6 mice purchased from either 
Harlan srl or Charles River. Interestingly, we found that 
mice purchased from Harlan (herein referred to as strain 
1) expressed the TT genotype, while those purchased from 
Charles River (herein referred to as strain 2) expressed the 
corresponding CC genotype (Figure 1B).
AIRE regulates MAGEB2 gene expression in 
mTECs by epigenetic mechanisms
To test whether the two allelic variants of mouse 
AIRE gene induce different levels of MA expression 
in mTECs, AIRE (GeneBank accession number: 
AF073797) and MAGEB2 (GeneBank accession number: 
AC097273.3) gene expressions were comparatively 
studied in mTECs from C57BL/6 mice strain 1 and 2. 
Figure 2A shows that relative AIRE and MAGEB2 gene 
expressions were significantly higher in mTECs from 
strain 1 than in those from strain 2 mice, and that AIRE 
gene expression in mTECs from each of the two strains 
could be efficiently silenced by both siRNAs SI0211352 
and S100186424. Importantly, AIRE gene silencing also 
abolished the expression of MAGEB2 gene but not that 
of the AIRE non-dependent GAD1 gene (GeneBank 
accession number: AC097273.3). In these experiments 
AIRE gene silencing was effective since AIRE protein 
was detectable in untreated mTECs from both strains of 
C57BL/6 mice, but neither in the same cells treated with 
the two AIRE-specific siRNA nor in RMA-S control cells 
(Figure 2B).
Gene sequence analysis of MAGEB2 and relative 
proximal gene regions by the Pattern matching/DNA-
pattern tools (http://rsat.ulb.ac.be/rsat) revealed six 
potential AIRE-binding sites (T-boxes and G-boxes) [24] 
located from 0.5 kb to approximately 10 kb upstream ATG 
initiation codon of MAGEB2 gene (Figure 2C). Since 
the expression of MAGE genes is regulated by DNA 
demethylation [25], and epigenetic control of methylation 
is one of AIRE mechanisms of action [26], the methylation 
status of the CpG islands upstream the MAGEB2 gene in 
Figure 2: AIRE regulation of MAGEB2 gene expression. A. Gene expression of AIRE, MAGEB2 and GAD1 in mTECs treated 
or not with two AIRE-specific siRNA evaluated by real time PCR. White and black columns refer to mTECs extracted from C57BL/6 mice 
strain 1 and 2, respectively. The results are the mean of three independent experiments. B. Western blot analysis of AIRE protein expression 
in mTECs from both C57BL/6 mice strain 1 and 2 treated or not with AIRE-specific siRNA, and in RMA-S cells, used as a negative control. 
C. Localization of AIRE-binding sites (T-boxes and G-boxes) from 0.5kb to approximately 10 kb upstream to ATG initiation codon of the 
MAGEB2 gene. The vertical bars locate the binding sites. D. Methylation analysis of CpG island 2 of the MAGEB2 gene in mTECs, treated 
or not with the AIRE-specific siRNA SI0211352, and in B16F10 melanoma cells. DNA was predigested with FNU4H1 restriction enzyme, 
which does not degrade methylated DNA. Then, specific primers were used to selectively amplify the CpG 2 island by PCR. Agarose gel 
electrophoresis shows the presence of a gene amplification product (350 pb) in the columns corresponding to undigested DNA from mTECs 
(c) or digested DNA from mTECs pretreated with the AIRE-specific siRNA (d), but not from untreated mTECs (b) or B16F10 cells (a). The 
results of one representative experiment out of two are shown.
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mTECs treated or not with an AIRE-specific siRNA was 
evaluated. Three CpG islands (1, 2, 3) located 59.794, 
474.936, and 678.816 kilobases upstream the MAGEB2 
initiation codon (UCSC database), respectively, were 
analyzed. In order to selectively amplify methylated 
genomic regions, mTECs DNA was pre-digested with 
FNU4H1 enzyme, which degrades only demethylated 
DNA. Interestingly, a band corresponding to CpG island 2 
of MAGEB2 gene was observed after PCR amplification 
of DNA from mTECs pre-treated with an AIRE-specific 
siRNA but not from untreated mTECs or B16F10 
melanoma cells, which costitutively express MAGEB2 
(Figure 2D). No differences were detected concerning 
CpG islands 1 and 3 (not shown). 
Identification of MAGEB2-derived immunogenic 
peptides
MAGEB2256-264 (SDPPSYEFL) and MAGEB2134-142 
(KYKEQFPEI) peptides were selected as potential high 
and low H-2 Kb binders, respectively, based on their 
relative binding scores (66.000 vs 0.720, respectively), 
using the BIMAS epitope prediction software (www-
bimas.cit.nih.gov). 
To validate the results of this analysis, the MHC 
class I antigen stabilization assay was performed using 
TAP-deficient RMA-S cells, which express surface MHC 
class I antigen only when pulsed with an exogenous 
peptide. In this stabilization assay, the percentage of 
Figure 3: Frequency and cytotoxic activity of MAGEB2
256-264
 peptide-specific CD8+ T cells. A. MHC-I stabilization 
assay performed pulsing RMA-S cells with either the MAGEB2134-142 or the MAGEB2256-264 peptide. The results refer to one out of three 
experiments and are expressed as percentages of positive cells. The mean values ± SD of the three experiments and relative statistically 
significant differences, calculated by paired t test, are reported in the histogram. (b) Frequency of IFNγ secreting T cells and (c) cytotoxic 
activity (D) of different CD8+ T cell populations incubated in the presence of either RMA-S cells, pulsed or not with MAGEB2 peptides, 
or B16F10 melanoma cells. Unstimulated CD8+ T splenocytes (⬜), CD8+ T splenocytes cultured for 5 days in the presence of syngeneic 
DC pulsed with MAGEB2256-264 peptide ( ) and CD8+ T splenocytes cultured for 5 days in the presence of syngeneic DC pulsed with 
MAGEB2134-142 peptide () were used as effector cells. Non-pulsed RMA-S (a, d, g), RMA-S pulsed with MAGEB2256-264 peptide (b, e), 
RMA-S pulsed with MAGEB2134-142 peptide (h) and B16F10 melanoma cells (c, f, i) were used as targets. Effector:target ratio was 10:1 
for (C) and 20:1 for (D). The figures show the results of one out of three experiments. Results are expressed as mean values of duplicate 
wells. The statistically significant differences of frequencies or cytotoxic activity among different CD8+ T cell populations, calculated by 
unpaired t test, are indicated. 
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Figure 4: rs1800522 SNP regulates MAGEB2 expression and MAGEB2-specific T cell survival. A. Percentage of apoptotic 
MAGEB2256-264 specific CTL cultured for 24 h alone or with mTECs from either C57BL/6 strain 1 (white columns) or 2 (black columns) 
mice untreated or treated with the AIRE-specific siRNA SI0211352. The data are the mean of 3 independent experiments. Each experiment 
was performed in triplicates. B. Frequency of IFNγ secreting cells in MAGEB2256-264 specific CTL cultured for 24 h alone or with mTECs 
from either C57BL/6 strain 1 (white columns) or 2 (black columns) mice untreated or treated with the AIRE-specific siRNA SI0211352. The 
data are the mean of 3 independent experiments. Each experiment was performed in triplicates. C. Percentage of apoptotic MAGEB2256-264 
specific CTL cultured for 24 h in culture medium alone (a) or in the presence of wild type mTECs (bearing the TT genotype) (b), transgenic 
mTECs (bearing the CC genotype) (c), AIRE silenced mTECs (d). The data are the mean of 3 independent experiments. Each experiment 
was performed in triplicates. D. Frequency of IFNγ secreting MAGEB2256-264 specific CTL cultured for 24 h alone (a) or in the presence of 
wild type mTECs (bearing the TT genotype) (b), transgenic mTECs (bearing the CC genotype) (c), AIRE silenced mTECs (d). The data are 
the mean of 3 independent experiments. Each experiment was performed in triplicates. E. Percentage of apoptotic MAGEB2256-264 specific 
CTL cultured for 24 h alone or with mTECs from C57BL/6 strain 1 in the presence or not of an anti-FasL mAb (0.5 µg/ml). A gate was 
established on CD3+CD8+ T lymphocytes. The dot plots show the percentages of apoptotic CD3+CD8+ T cells (positive for annexin V 
staining and negative for 7AAD staining) in the different culture conditions. An isotype-matched mAb was used as a control: under these 
culture conditions the percentage of apoptotic CD3+CD8+ T cells was comparable to that of CD3+CD8+ T cells cultured with mTECs in 
the absence of the antibody (not shown). The results of one representative experiment out of three are shown.
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RMA-S cells expressing MHC class I antigens was 88% 
when the cells were pulsed with the MAGEB2256-264 
peptide, while it was 27% following pulsing with the 
MAGEB2134-142 peptide (Figure 3A). 
Then, the immunogenicity of these peptides was 
analyzed by Elispot and by cytotoxic assay. In these 
assays C57BL/6 mouse splenocytes were stimulated 
with syngeneic dendritic cells (DC) pulsed either with 
the MAGEB2256-264 or the MAGEB2134-142 peptide. The 
results of these assays showed that the stimulation with 
the MAGEB2256-264 peptide induced a higher frequency of 
IFNγ secreting cells and a higher cytotoxic activity than 
stimulation with the MAGEB2134-142 peptide (Figures 3B 
and 3C). Hence, the MAGEB2256-264 peptide showed to be 
more immunogenic than MAGEB2134-142 peptide. 
AIRE rs1800522 SNP modulates the apoptotic 
rate in MAGEB2-specific cytotoxic T lymphocytes 
(CTL) exposed to mTECs
MAGEB2256-264 peptide-specific CTL from strain 1, 
cultured in the presence of syngeneic mTECs, showed a 
higher extent of apoptosis (Figure 4A and Supplementary 
Figure 5: Effects of MAGEB2 vaccination in B16F10 melanoma-challenged C57BL/6 strain 1 and 2 mice. A. Melanoma 
growth curves. Growth curves of B16F10 melanoma in C57BL/6 strain 1 (white symbols) and 2 (black symbols) mice vaccinated (triangles) 
or not (circles) with syngeneic MAGEB2256-264 peptide-pulsed DC. Unpaired t test analyses were performed to verify the existence of 
statistically significant differences between untreated strain 1 and strain 2 groups or between vaccinated strain 1 and strain 2 groups in 
day-times needed by the tumor to reach either 40 mm2 or 100 mm2 dimensions. *: P < 0.05. Similar analyses comparing untreated with 
vaccinated strain 1 or untreated with vaccinated strain 2 groups showed the existence of highly significance statistical differences (P < 
0.0001). B.-E. Frequency and cytotoxic activity of MAGEB2256-264 peptide-specific CD8+ T cells from strain 1 and strain 2 mice after 
MAGEB2 immunization and tumor challenge. (B) and (C) panels refer to analyses performed on splenocytes; (D) and (E) panels refer 
to analyses performed on Tumor Infiltrating Lymphocytes (TIL). In all panels white bars indicate analyses executed on C57BL/6 strain 1 
mice, while black bars indicate analyses executed on C57BL/6 strain 2 mice. (B) and (D) panels show the frequency of T cells specifically 
secreting IFNγ after incubation with MAGEB2256-264 peptide-pulsed RMA-S cells (Elispot analyses); the effector:target ratio was 10:1. Non-
pulsed RMA-S cells were used as negative control: the number of spots in wells containing effector cells and non-pulsed RMA-S cells was 
considered as non-specific background. Data are presented as: frequency of spots in cultures of effector cells plus MAGEB2256-264 peptide-
pulsed RMA-S cells - frequency of spots in cultures of effector cells plus non-pulsed RMA-S cells. (C) and (E) panels show the cytotoxic 
activity exerted by effector lymphocytes (splenocytes or TIL) against MAGEB2256-264 peptide-pulsed RMA-S cells (cytotoxic assay); the 
effector:target ratio was 20:1. Cultures of effector cells plus non-pulsed RMA-S cells were used as negative control.
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Figure 1) and a reduced frequency (Figure 4B) than 
corresponding CTL from strain 2 mice cultured with 
syngeneic mTECs. In the presence of a neutralizing anti-
Fas ligand mAb the extent of apoptosis of MAGEB2256-264 
peptide-specific CTL co-cultured with syngeneic mTECs 
was comparable to that of CTL cultured alone (Figure 4E), 
suggesting that a Fas-dependent mechanism was involved. 
Hence, the TT AIRE genotype, present in C57BL/6 
mice strain 1, is associated with higher MAGEB2 gene 
expression and greater extent of apoptosis of MAGEB2-
specific CTL than the corresponding CC genotype. In 
agreement with these observations, spectratyping of 
the T cell receptor (TCR) complementary determining 
region (CDR) 3 of MAGEB2256-264-specific CTL, showed 
different T cell repertoires when the cells were cultured 
alone, in the presence of untreated mTECs or in the 
presence of AIRE silenced mTECs, supporting the direct 
role played by AIRE in modulating the T cell repertoire 
(Supplementary Figure 2). 
To confirm these data, mTECs from strain 1 were 
made transgenic for the C allelic variant (Supplementary 
Figure 3A) and the relative functions were analyzed. 
AIRE and MAGEB2 genes displayed a significantly lower 
expression in mTECs bearing the CC transgenic genotype 
than in non-transgenic mTECs, and were efficiently 
silenced by an AIRE-specific siRNA (Supplementary 
Figure 3B). Non-transgenic mTECs, co-cultured with 
syngeneic MAGEB2256-264 peptide-specific CTL, induced 
a higher extent of apoptosis (Figure 4C) and a lower 
frequency of MAGEB2256-264 peptide-specific CTL (Figure 
4D) than transgenic mTECs.
B16 melanoma tumor growth in C57BL/6 mice 
strain 1 and 2 immunized against MAGEB2
To assess the in vivo relevance of AIRE functional 
differences related to rs1800522 SNP, B16F10 melanoma 
tumor growth was comparatively measured in mice from 
strain 1 and 2. Tumor growth was significantly (p<0.05) 
lower in strain 2 than in strain 1 mice until the 10th day 
from tumor challenge, but not at later stages (Figure 5A). 
However, when both strains were immunized before tumor 
challenge with syngeneic DC pulsed with MAGEB2256-264 
peptide, melanoma tumor growth was significantly 
(p<0.05) lower in strain 2 than in strain 1 mice at all 
time-points (Figure 5A). Interestingly, higher frequency 
of MAGEB2256-264 peptide-specific IFNγ secreting T cells 
and higher CD8+ T cell cytotoxic activity were observed 
in strain 2 than in strain 1 mice (Figures 5B, 5C, 5D, 5E). 
DIscUssION
The results of our study show that: a) AIRE controls 
MAGEB2 expression by mTECs through an epigenetic 
mechanism; b) variant alleles of the rs1800522 SNP 
of human AIRE gene differently regulate MAGEB2 
expression by mTECs; c) mTECs expressing different 
MAGEB2 levels under the control of variant alleles of 
AIRE induce different extent of apoptosis in MAGEB2-
specific CTL; and d) the C allelic variant of AIRE 
rs1800522 SNP (protective in humans) is associated with a 
more effective MAGEB2-specific T cell immune response 
than the corresponding T allelic variant.
Human MAGEB2 antigen displays a high degree of 
homology with its mouse counterpart (BLAT analysis by 
UCSC genome browser) and is associated with a T cell-
specific protective immune response [27]. We show here 
that AIRE regulates MAGEB2 gene expression through 
gene demethylation, suggesting that the modelling of 
MAGEB2-specific T cell repertoire is under the direct 
control of AIRE. On this basis, variations of AIRE gene 
activity, due to polymorphisms or gene alterations, could 
be related to protection or susceptibility to melanoma, as 
supported by several lines of evidence in humans [15] 
and in animals [28]. Interestingly, we observed that the C 
variant allele of the AIRE gene sequence corresponding 
in mice to human rs1800522 SNP induced lower 
MAGEB2 gene expression in mTECs and, subsequently, 
lower MAGEB2-specific, Fas-dependent CTL apoptosis 
than the C variant allele present in mTECs of strain 
2 mice. Accordingly, strain 2 mice, bearing the AIRE 
CC genotype, protective in humans [15], showed in the 
periphery higher frequency of MAGEB2-specific T cells 
and higher MAGEB2-specific T cell cytotoxicity than 
strain 1 mice bearing the AIRE TT genotype. Indeed, 
vaccination with MAGEB2256-264 -peptide had a higher 
protective efficiency against B16F10 melanoma tumor 
growth in strain 2 than in strain 1 mice. Hence, for the 
first time our data elucidate, at the genetic and molecular 
level, the processes linking the expression of a specific 
AIRE gene polymorphism to susceptibility to a neoplastic 
disease such as melanoma. This finding allows one to 
envisage the possibility to map single individuals in order 
to predict genetic predispositions to tumor development, 
which could be counteracted by adoption of opportune 
preventive interventions or by specific immunotherapy. 
MATERIALS AND METHODS
Mice
Six-12 week old C57BL/6 female mice (H-2 Kb/
Db) were purchased from Harlan Srl (Indianapolis, IN) 
and from Charles River (Wilmington, MA) between 
January 2011 and December 2014. The protocol here 
adopted received approval by the Ethics Committee 
for Experimentation on Animals of IRCCS Azienda 
Ospedaliera Universitaria San Martino-IST of Genoa.
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Cell lines
RMA-S MHC class I antigen negative mutant 
mouse lymphoma cells [29] were a kind gift of Dr. G. 
Pietra (Advanced Biotechnology Center, Genoa) while 
B16F10 melanoma cells (syngeneic to C57BL/6 mice) 
were purchased from ATCC. Both cell lines were received 
in 2012: since then, the cell lines were tested at six-month 
intervals. In particular, RMA-S cells were analyzed for 
the deficient expression of MHC class I antigens using the 
MHC class I-specific mAb clone 28-8-6 (PE, Biolegend, 
San Diego, CA); B16F10 cells were analyzed by RT-PCR 
and gene sequencing on amplified cDNA for MAGEB2 
MA gene expression. RMA-S and B16F10 cell lines were 
grown at 37 C in a 5% CO2 atmosphere in RPMI-1640 
medium (SIGMA, St. Louis, USA) supplemented with 
10% FCS, 2 mM L-glutamine, 10 mmol HEPES, 100 
mmol non-essential amino acids, 100 U/ml penicillin, 100 
µg/ml streptomycine, and 1% sodium pyruvate (referred 
to as culture medium). 
T cell sorting
TILs were purified from melanoma tumors 
filtering minced tissues using sterile cell strainers 
(Falcon, BD Biosciences, San Josè, CA). Collected 
cells were centrifuged on Ficoll gradient. Total T 
lymphocytes were sorted from TIL using Dynabeads® 
FlowComp™ Mouse Pan T (CD90.2) isolation kit 
(Invitrogen by Life Technologies Ltd., Paisley, UK) 
following the manufacturer’s instructions. The purity 
of total T lymphocyte preparations was monitored 
by flow cytometric analysis of cells stained with the 
allophycocianin (APC)-cyanin (Cy) 7 conjugated anti-
CD8 monoclonal antibody (mAb) clone 53-6.7 and 
the Peridinin Chlorophyll Protein Complex-cyanin 5.5 
(PerCP-Cy5.5) anti-CD3 mAb clone 145-2C11 (BD 
Bioscience, New Jersey, USA).
Generation of mTEC cultures
mTECs were isolated as previously described [30]. 
They were cultured in DMEM medium supplemented with 
D-valine (94 µg/ml), glutathione (0.1 mg/ml), ascorbic 
acid (50 µg/ml), insulin (0.4 µg/ml), L-glutamine (0.58 
mg/ml), 10% FCS and 1% Pen/Strep antibiotics in 6 
well-plates. Cells were phenotypically characterized by 
flow cytometry using the EpCAM-specific monoclonal 
antibody (mAb) G8.8 (Biolegend, San Diego, CA) and 
the MHC class-II antigen-specific mAb clone 25-9-17 (BD 
Biosciences, Franklin Lakes, NJ). 
Expression of AIRE, MAGEB2 and Glutamate 
decarboxylase 1 (GAD1) genes in mTECs
AIRE, MAGEB2 and GAD1 gene expression 
was analyzed by PCR and real time PCR as previously 
described [31]. Briefly, 48 µl of RNA, isolated using 
the OMNIZOL RNA Isolation kit (EuroClone, London, 
UK), were treated with 6 U DNase I and reverse 
transcribed into cDNA using Oligo(dT) 20Primer 
and Superscript II Reverse Transcriptase, followed 
by RNase H digestion. The amplification program 
included: a single denaturation step at 94 ºC for 3 min 
followed by either 35 (for MAGEB2), or 30 (for AIRE 
and for β-actin) cycles at 94ºC for 1 min, then 54–
62ºC for 1 min and 72ºC for 2 min, followed by a final 
extension step at 72ºC for 10 min. The following sense 
and antisense, respectively, oligonucleotide pairs were 
used: AIRE, 5’-GCAACTCTGGCCTCAAAGAG-
3’and 5’-GGTCTGAATTCCGTTTCCAA-3’; 
MAGEB2, 5’-GAGCTTGATCCACGAGTT-3’ 
and 5’-AGGAGACCTGTCCTGTCCTAGGC-3’; 
GAD1, 5’-ATAGAAAGGGCCAATTCAGTC-3’, 
and 5’ -TGCATCCTTGGAGTATACCC-3’; β-act, 
5’- TCATGAAGTGTGACGTTGACATCCGT-3’ and 
5’-GTCAGGATCTTCATGAGGTAGTC-3’. In order to 
obtain quantitative measures of AIRE and MAGEB2 gene 
expression, quantitative real time PCR was performed 
using the LightCycler thermocycler and the SYBR Green 
Master Mix (Roche Diagnostics, Mannheim, Germany). 
The same primers were used for the real time PCR. AIRE 
and MAGEB2 PCR products were confirmed by sequence 
analysis.
AIRE gene silencing
SI0211352 and S100186424 AIRE-specific siRNA 
(Qiagen, Hilden, Germany) were used for silencing 
AIRE gene expression in mTECs. The sequences of 
sense and antisense strands of AIRE-specific siRNA were 
respectively: 5’-GGAAGAUCCAAGAAGUGCATT-3’ 
and 5’-UGCACUUCUUGGAUCUUUCCTG-3’ for 
SI0211352; 5’-GUGGCAAUUUGAAGAACAATT3’ 
and 5’-UUGUUCUUCAAAUUGCCACTG-3’ for 
S100186424. mTECs (4x105) were transfected with 
2.5 μg of AIRE-specific siRNA using the liposomal 
transfection reagent (Roche, Mannheim, Germany). 
Cells were cultured for 24 h at 37°C in culture medium 
before extracting total RNA and quantifying AIRE mRNA 
expression by Real Time PCR.
AIRE gene product detection by western blot
mTECs were pelleted in cold lysis buffer containing 
50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% NP-40, and 
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a protease inhibitor cocktail (G-Bioscience, St. Louis, 
MO). Protein concentration was determined by the Bio-
Rad Protein Assay (Bio-Rad Laboratories Inc, Hercules, 
CA) and AIRE protein was detected by western blot [32] 
using AIRE-specific rabbit antibodies (1:1000, Millipore, 
Billerica, MA), peroxidase-conjugated goat anti-rabbit 
IgG antibodies (1:2000, Millipore, Billerica, MA) and 
the Western Blotting Luminol Reagent (Roth, Karlsruhe, 
Germany).
Generation of transgenic mTECs expressing the 
CC AIRE genotype at the rs1800522 SNP site
A plasmid shuttle vector bearing the CC genotype 
of rs1800522 SNP was prepared as previously described 
[24]. Briefly, we cloned in the SacII unique cloning 
site of pcDNA3.1/V5-His-TOPO plasmid (Invitrogen, 
Carlsbad, CA) a 400 pb AIRE gene sequence. To this 
aim, a bacterial artificial chromosome containing the 
C57BL/6 AIRE gene sequence (RPCI23.C 278E6 clone, 
Life Technologies, Paisley, UK), selected according to 
UCSC database, was used as template and in situ-direct 
mutagenesis of the wild-type TT genotype was performed 
using AIRE 5’-tccccgcggtggaaaaactgaggaccttctcca-3’ 
and 5’-tccccgcggcaggagtataccccccgaaa-3’ external 
primers as well as 5’-tcagcactcatttgacggcatcctg-3’ and 
5’-caggatgccgcaaatgagtgctga-3’ internal primers designed 
on the polymorphic sequence. Plasmid sequence was then 
analysed to monitor the AIRE genotype substitution.
This plasmid, containing the G418 resistance gene, 
was used as a partner in homologous recombination 
[33]. mTECs (5x105) were transfected overnight with 2 
µg of plasmid using a Polifect transfection kit (Qiagen, 
Hilden, Germany) and selected and expanded in medium 
supplemented with G418 (1 mg/ml). Total cellular DNA 
from growing colonies was sequenced to confirm that 
recombination had occurred. 
Identification of AIRE-binding sites on MAGEB2 
promoter gene
The Pattern matching/DNA-pattern tools (http://
rsat.ulb.ac.be/rsat) was used to predict AIRE transcription 
factor binding sites (T-boxes and G-boxes) located 
from 0.5 kb to 10 kb upstream ATG initiation codon of 
MAGEB2 gene [24]. 
CpG methylation pattern analysis of MAGEB2 
upstream promoter sequences
DNA was digested with FNU4H1 (Biolabs, Ipswich, 
MA), a restriction enzyme sensitive to methylation. 
Digested and undigested DNA were used as templates for 
PCR performed with specific primers designed on CpG 
islands of MAGEB2 gene sequence selected according to 
UCSC genome browser database. The following specific 
primers were selected according to UCSC genome browser 
database: CpG 1, 5’-CGTCCCCCTCTGCGCCT-3’ 
and 5’-TTCCCGAGACACGTGCGTTTGCTGA-3’; 
CpG 2, 5’-GGCTGGTCTCCGGGGTGA-3’ and 
5’-CTTCGTCAGCTGGTCGCACCC-3’; CpG 
3 5’-GCAGAACCCACGGTCTCGC-3’ and 
5’-GATCAAGCCCCTCCACCCCCA-3’. PCR products 
were then sequenced. 
Gene sequencing
Gene sequencing was performed as described [34]. 
Briefly, DNA sequencing was carried out using an ABI 
3130XL automated sequencer (Applied Biosystems, 
Foster City, CA). DNA sequence analyses were performed 
on PCR products amplified using forward primers specific 
for AIRE (5’-TGACTTCTTGTAACGATG-3’), MAGEB2 
(5’-GAGCTTGATCCACGAGTT-3’), or for CpG island 
sequences (CpG1: 5’-CGTCCCCCTCTGCGCCCT-3’, 
CpG2: 5’-GGCTGGTCTCCGGGGTGA-3’, CpG3: 
5’-GCAGAACCCACGGTCTCGC-3’). 
Epitope prediction and peptide synthesis
Potential H-2 Kb binder 9mer peptides from 
MAGEB2 murine protein were identified using the 
BIMAS epitope prediction software (www.bimas.cit.
nih.gov). Peptides were synthesized using the standard 
method of solid-phase peptide synthesis, which follows 
the 9-fluorenylmethoxycarbonyl (Fmoc) strategy with 
minor modifications [35, 36]. 
MHC class I antigen stabilization assay
MHC class I antigen stabilization assay was 
performed as described [37, 38]. Briefly, RMA-S cells 
were cultured at 26°C overnight and washed with PBS. 
Then, cells (1x106 cells/ml in RPMI-1640 medium) were 
incubated at 37°C for 1 hour with either MAGEB2256-264 
(50 µg/ml) or MAGEB2134-142 peptides (50 µg/ml). After 
washings, cells were stained with the labelled MHC class 
I antigen-specific mAb clone 28-8-6 (PE, Biolegend, San 
Diego, CA) and analyzed with a FACSCanto cytometer 
(BD Biosciences, New Jersey, USA).
Splenic CD8+ T cell purification
CD8+ splenic T cells were enriched by 
immunomagnetic cell sorting using the MACS system 
(Milteny Biotec, Bergisch Gladbach, Germany). CD8+ T 
cell enrichment (> 95%) was monitored by FACS analysis 
using the FITC-conjugated CD8-specific mAb clone 53-
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6.7 and the APC-Cy7 labelled CD3-specific mAb clone 
145-2C11 (BD Bioscience, Franklin Lakes, NJ).
Generation of DC from murine bone marrow cells
DC were generated as described [39]. Briefly, bone 
marrow was flushed from the long bones of the hind limbs 
of 10-14 week old female C57BL/6 mice. The cells were 
cultured in DC medium consisting in RPMI supplemented 
with 10%FCS, 2 mmol/l L-glutamine, 10 mmol HEPES, 
100 mmol non-essential amino acids, 100 U/ml penicillin, 
100 µg/ml streptomycine, 50 µmol β- mercaptoethanol, 20 
ng/ml GM-CSF (Sigma-Aldrich, St. Louis, USA). On day 
6 or 7 of culture, released mature non-adherent cells with 
the typical features of DC were used for in vitro studies.
 DC were phenotypically analyzed using CD11c-
specific mAb clone 2D7, PE-Cy7 , CD86-specific mAb 
clone GL1, APC, MHC class II antigen—specific mAb 
clone 25-5-17, FITC (Biolegend, San Diego, CA): >90% 
of cells showed high expression of these markers.
MAGEB2-specific CTL generation
DC (2x106) were pulsed with either MAGEB2256-264 
or MAGEB2134-142 peptide at 10 ng/ml for 1 hour at 37 °C. 
Peptide-pulsed DC (5x104 cells/well) were incubated for 
10 days at 37 °C with purified splenic CD8+ T cells (5x105 
cells/well) seeded in 24-well plates. IL-2 Recombinant 
Mouse Protein (50 IU/ml) (Invitrogen, Carlsbad, CA) 
and MAGEB2256-264 peptide (70 ng/ml) were added to the 
cultures on days 1, 4 and 7. Cells were then expanded by 
repeated stimulations with peptide-pulsed DC (1x103 cells/
well) and IL-2 (50 IU/ml). 
Enzyme-linked immunospot assay (ELISPOT)
ELISPOT was performed using the INF-γ enzyme-
linked immunospot antibody Pair, Mouse (Millipore, 
Billerica, MA) following the manufacturer’s instructions. 
Responder cells (TILs isolated from melanoma 
tumors, CD8+ T cells isolated from fresh splenocytes, 
MAGEB2256-264 or MAGEB2134-142 peptide-specific CD8
+ 
T cells) (1x105/well) were incubated with homologous 
peptide-pulsed RMA-S cells (1x104/well) or B16F10 
cells (1x104/well) in a final volume of 100 µl. Spots were 
counted using a BioReader 3000 Elispot Reader (Bio-Sys 
GmbH). 
Cytotoxic assay
The assay was performed as described [40]. 
Briefly, RMA-S cells (5x103 cells/well) pulsed with the 
MAGEB2256-264 peptide, or B16F10 cells (5x10
3 cells/
well) were stained with carboxyfluorescein diacetate 
succinimidyl ester (CFSE) and cultured with MAGEB2-
specific CTL effector cells (1x105 cells/well), or freshly 
purified CD8+ splenocytes (1x105 cells/well) as negative 
control. After 4 hour incubation at 37° C cells were stained 
with 7-Amino-actinomycin D (7-AAD). Spontaneous 
target cell lysis and lysis of non-pulsed RMA-S cells 
were considered as background. The mean percentage of 
specific lysis was calculated as follows: % specific lysis 
=[(viable target cells of control sample-viable target cells 
of test sample)/ viable target cells of control sample] x 
100. The assay was performed in duplicate. 
TCR CDR3 spectratyping
MAGEB2256-264-specific CTL (1x10
6 cells/well) 
from strain 1 mice were cultured for 24 h alone or co-
cultured with either untreated syngeneic mTEC (5x105 
cells/well) or with syngeneic mTEC (5x105 cells/well) 
silenced for the expression of AIRE gene as above 
described. TCR CDR3 length analysis, also referred 
as Spectratyping or Immunoscope, was performed as 
follows. cDNAs recovered from the different samples and 
culture conditions were amplified under non-saturating 
PCR conditions with TCR-Vβ family-specific primers, as 
described [41-43]. Each different PCR product was run in 
a fluorescence-based DNA sequencer (ABI 377; Applied 
Biosystems) with Rox-labeled size markers (Applied 
Biosystems). The data were analyzed using Genescan 
software (Applied Biosystems) to assign size and peak 
areas to the different PCR products.
Analysis of CTL apoptosis and inhibition of Fas-
mediated apoptosis
CTL apoptosis was analyzed incubating 
MAGEB2256-264-specific CTL (1x10
5 cells/well) for 24h 
at 37 °C with mTECs (1x105 cells/well) expressing 
either the TT or the CC genotype of AIRE gene in 100 
µl final volume of culture medium. Non-adherent cells 
were, then, harvested, viable cells counted by 7AAD 
exclusion, and stained with FITC annexin V kit as well as 
CD8-specific APC-mAb (Biolegend). FACS analysis was 
then performed using the FACSCanto flow cytometer. A 
blocking hamster IgG anti-mouse Fas ligand mAb (clone 
MFL3, eBioscience, San Diego, CA) was used to study the 
dependency of mTEC-induced CTL apoptosis on Fas-Fas 
ligand interaction. To this aim, mTEC were co-cultured 
with CD8+MAGEB2256-264 specific T cells for 24h in the 
absence or the presence of a hamster IgG anti-mouse 
Fas ligand mAb (clone MFL3, Ebioscience, New Jersey, 
USA), blocking Fas-mediated cell death (used at either 
0.5 or 2.5 µg/ml concentrations). A unrelated, isotype-
matched mAb (clone MAR-1, Ebioscience, New Jersey, 
USA) was used as control. The analysis of apoptosis on 
CD8+MAGEB2256-264-specific T cells was performed as 
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above described. The experiments were repeated 3 times 
in duplicate. 
Vaccination with MAGEB2256-264 loaded DC of 
C57BL/6 mice bearing TT or CC AIRE genotype
Before being challenged with B16F10 melanoma 
cells, both C57BL/6 strain 1 and strain 2 mice were 
immunized with MAGEB2256-264 peptide-pulsed DC, 
as follows. Syngeneic DC (2x106 cells), pulsed with 
MAGEB2256-264 peptide (50 µg) for 1 h at 37 °C, were 
intradermally injected at the base of the tail of each 
mouse. Immunizations were performed on days -21, -14 
and 0 with respect to tumor challenge. The day of the third 
immunization, B16F10 melanoma cells (1x105/0.1 ml of 
sterile PBS) were intradermally injected. The kinetics of 
melanoma growth was monitored by measurements with 
a microcaliper every other day. Mice were sacrificed when 
palpable tumors reached 10 mm of maximum diameter. 
Each sample group of animals included 6 mice; the 
experiments were repeated twice. 
Statistical analyses
The statistical significance of differences between 
means was analyzed using the Mann-Whitney t test 
for non-parametric values or the paired t test for paired 
measures. Calculations were performed using GraphPad 
Prism version 5.0 software: two sided tests were 
performed. The relative gene expression levels were 
calculated using the comparative Ct(∆∆t) method [44].
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